Devyser Diagnostics (DVYSR) CMD 2024 summary

Strategic direction and business development

• Focus on hereditary diseases (largest by revenue), oncology, and transplantation (fastest growing), aiming for leadership in fast, accurate, and easy-to-use genetic diagnostics.

• Shift of R&D resources toward next-generation sequencing (NGS) and software, while maintaining legacy fragment analysis products.

• Expansion of commercial organization and direct sales, especially in key European markets and the U.S., with four main sales channels: direct sales, partners, lab services, and distributors.

• Partnerships with Thermo Fisher and Illumina to drive U.S. market entry, regulatory progress, and increased partner-driven revenues.

• Investment in a CLIA-certified lab in the U.S. to support a dual business model: lab services and test kits.

Product innovation and pipeline

• Three new products planned for 2025: Genomic Blood Group Typing, Fetal Typing, and HLA Loss, all leveraging NGS.

• Enhanced software offerings, including AI-based tools for transplantation and transfusion medicine.

• Regulatory upgrades targeted for key products (CFTR and Thalassemia) to secure IVDR status and add features.

• Technical platform upgrade with absolute quantification of cell-free DNA, opening new diagnostic opportunities.

• Over 30 ongoing clinical studies and increased scientific publications, strengthening clinical validation and adoption.

U.S. market and reimbursement strategy

• Dual approach: offering both lab services (TransplantTrace) and test kits (Accept cell-free DNA) to transplant centers.

• Pursuing Medicare coverage via MolDX for lab services, with plans to leverage this for future kit reimbursement.

• Strategic partnerships with AdvaMed and C21 to navigate regulatory and reimbursement changes.

• FDA approval for Accept cfDNA and CFTR would enable localized testing, allowing transplant centers to capture testing revenue and improve patient care.

• Pricing strategy aims to undercut current alternatives while maintaining strong margins and hospital profitability.